- BCX-4430
-
- $10.00 / 1KG
-
2021-08-31
- CAS:222631-44-9
- Min. Order: 1KG
- Purity: 99.99%
- Supply Ability: 20 tons/month
|
| | 3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, monohydrochloride, (2S,3S,4R,5R)- Basic information |
| Product Name: | 3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, monohydrochloride, (2S,3S,4R,5R)- | | Synonyms: | 3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, monohydrochloride, (2S,3S,4R,5R)-;3,4-Pyrrolidinediol,2-(4-aMino-5H-pyrrolo[3,2-d]pyriMidin-7-yl)-5-(hydroxyMethyl)-, hydrochloride(1:1), (2S,3S,4R,5R)-;BCX 4430;(2S,3S,4R,5R)-2-(4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3,4-pyrrolidinediol monohydrochloride;BCX-4430
(BCX4430;Galidesivir);BCX4430;GALIDESIVIR;GALIDESIVIR HYDROCHLORIDE (BCX 4430 HYDROCHLORIDE) | | CAS: | 222631-44-9 | | MF: | C11H16ClN5O3 | | MW: | 301.73 | | EINECS: | | | Product Categories: | | | Mol File: | 222631-44-9.mol |  |
| | 3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, monohydrochloride, (2S,3S,4R,5R)- Chemical Properties |
| storage temp. | Store at -20°C | | solubility | H2O: 2 mg/mL, clear | | form | Solid | | color | White to off-white | | Water Solubility | Water : ≥ 41 mg/mL (135.88 mM) |
| | 3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, monohydrochloride, (2S,3S,4R,5R)- Usage And Synthesis |
| Uses | BCX 4430 is an antiviral drug, an adenosine analog). It is developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for Hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. | | in vivo | Galidesivir (BCX4430) hydrochloride is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir hydrochloride has demonstrated pronounced efficacy[1].
Galidesivir hydrochloride (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF)[4]. | Animal Model: | Female Syrian golden hamsters (hamsters infected with YF virus)[4] | | Dosage: | 4 mg/kg of body weight | | Administration: | I.p.; twice daily for 7 days | | Result: | Significantly improved the survival of hamsters infected with YFV. |
|
| | 3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, monohydrochloride, (2S,3S,4R,5R)- Preparation Products And Raw materials |
|